ArticleJournal of neuro-oncology2026
Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterations.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study compares clinical characteristics and survival between molecular (MolGBM) and histological IDH-wild-type (IDH-WT) glioblastoma (HistGBM), and further characterizes histological lower-grade IDH-WT astrocytic tumors without genomic GBM-defining alterations.
methodsAdult patients with histologically lower-grade IDH-WT astrocytoma (WHO grade 2-3) and available tumor tissue were included. Tumors were classified according to the 2021 WHO Classification of CNS tumors. Biopsy-only cases were excluded. IDH1 and TERT promoter (TERTp) mutations were analyzed via Sanger and whole-exome sequencing (WES). TERTp-WT tumors underwent WES and subsequent DNA methylation profiling. Clinical, molecular, and outcome data were collected.
resultsThe cohort comprised 47 surgically resected histologically lower-grade IDH-WT astrocytic tumors. Thirty-nine fulfilled WHO 2021 criteria for MolGBM, mainly based on TERTp mutation (n = 36), while eight lacked GBM-defining molecular alterations. Compared with HistGBM (n = 54), MolGBM more frequently presented with seizures and showed a lower Ki-67 index. Median overall survival (OS) was 19.8 months in MolGBM and 14.6 months in HistGBM, without a significant difference in univariable analysis (p = 0.11). Patients aged ≥ 60 years showed longer overall survival in the MolGBM group (17.9 vs. 12.3 months; p = 0.0079). In multivariable Cox regression adjusted for age, extent of resection, and completion of the Stupp regimen, MolGBM was independently associated with more favorable OS (HR 0.40, 95% CI 0.24-0.67, p = 0.0005). The eight tumors lacking GBM-defining alterations showed longer survival and marked diagnostic heterogeneity.
conclusionMolGBM showed comparable unadjusted OS but more favorable adjusted OS than HistGBM, supporting clinical and biological heterogeneity among molecularly defined IDH-WT diffuse glioma. IDH-WT, TERTp-WT lower-grade astrocytic tumors lacking GBM-defining alterations require comprehensive molecular characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.